Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Reuters

06-02

<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540089762"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540089762\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540089762?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540089762","market":"nz","top_or_hot":-1,"title":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLNQVCH:1","article_id":"2540089762","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540089762","pubTimestamp":1748862036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology  2025 Annual Meeting, the data demonstrates a median progression-free survival  of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Relay Therapeutics宣布启动RLY-2608治疗乳腺癌的3期ReDiscover-2研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RLAY":0.9},"content_text":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    \n\n        Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}